Authors

  • John Wilkinson
  • Frederick J Dorey

DOI:

https://doi.org/10.5912/jcb128

Abstract

Cambridge Antibody Technology (CAT) won its High Court battle against healthcare company Abbott over the level of royalties due on sales of the potential blockbuster drug Humira. CAT argued successfully that it was due a royalty of just over 5 per cent of sales, rather than the 2 per cent that Abbott had been paying. It is believed that CAT is due back payments from Abbott as well as future royalty payments at the higher rate on sales predicted to rise to over US$2bn per year.

Downloads